Picture of Hyundai BioLand Co logo

052260 Hyundai BioLand Co Share Price

0.000.00%
kr flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-10.89%
3m-10.86%
6m-18.66%
1yr-24.08%
Volume Change (%)
10d/3m+60.9%
Price vs... (%)
52w High-37.87%
50d MA-5.81%
200d MA-12.62%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital6.27%
Return on Equity6.07%
Operating Margin8.46%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueKR₩m106,310.8688,898.82102,801.8399,153.53101,690.82n/an/a0.22%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-28.47n/an/a+26.48-10.7n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Hyundai BioLand Co EPS forecast chart

Profile Summary

Hyundai Bioland Co Ltd, formerly SK Bio Land Co Ltd, is a Korea-based company mainly engaged in the development and manufacture of raw materials for cosmetics. The Company operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
September 1st, 1995
Public Since
May 17th, 2001
No. of Employees
258
Sector
Personal & Household Products & Services
Industry
Consumer Defensives
Exchange
kr flag iconKorea Exchange - KOSDAQ
Shares in Issue
15,000,000

052260 Share Price Performance

Upcoming Events for 052260

Q1 2024 Hyundai BioLand Co Ltd Earnings Release

Q2 2024 Hyundai BioLand Co Ltd Earnings Release

Similar to 052260

Picture of Barunson Co logo

Barunson Co

kr flag iconKorea Exchange - KOSDAQ

Picture of BeautySkin Co logo

BeautySkin Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Bonne Co logo

Bonne Co

kr flag iconKorea Exchange - KOSDAQ

Picture of C&C International Co logo

C&C International Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Clio Cosmetics Co logo

Clio Cosmetics Co

kr flag iconKorea Exchange - KOSDAQ

FAQ